Beam Therapeutics Inc is trading at $32.45 (+9.80%) as investors react positively to new clinical data and regulatory updates for its key drug candidates presented around its Annual General Meeting on June 3.
- The rally is reportedly driven by fresh positive data from its BEAM-302 (for alpha-1 antitrypsin deficiency) and BEAM-101 (for sickle cell disease) programs.
- Investor sentiment is further boosted by the company's plans to seek accelerated FDA approval for its AATD therapy and to file a Biologics Licensing Application (BLA) for its sickle cell disease candidate by the end of 2026, marking a key step toward commercialization.